 Following the Independent Review Committees assessment, Affimed NV NASDAQ: AFMD will continue enrollment in Phase 2 REDIRECT trial evaluating AFM13 as a monotherapy for relapsed or refractory CD30-positive peripheral T-cell lymphoma PTCL. The study will continue and combine cohorts of CD30 high and CD30 low expressing PTCL. 